{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T19:26:57Z","timestamp":1789673217642,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-024-03382-w","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:02:25Z","timestamp":1725289345000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of pembrolizumab plus cisplatin and fluorouracil in radical treatment for patients with T4b esophageal squamous cell carcinoma"],"prefix":"10.1186","volume":"24","author":[{"given":"Nobukazu","family":"Hokamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeo","family":"Fukagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kiyokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Horikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naruyoshi","family":"Soeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kaneshiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Kodashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatsugu","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Oshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sasajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiro","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenshiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"3382_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.radonc.2021.02.031","volume":"158","author":"B Chen","year":"2021","unstructured":"Chen B, Deng M, Yang C, et al. High incidence of esophageal fistula on patients with T4b clinical esophageal squamous cell carcinoma who received chemoradiotherapy: a retrospective analysis. Radiother Oncol. 2021;158:191\u201399. https:\/\/doi.org\/10.1016\/j.radonc.2021.02.031.","journal-title":"Radiother Oncol"},{"key":"3382_CR2","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1200\/JCO.1997.15.1.277","volume":"15","author":"M Al-Sarraf","year":"1997","unstructured":"Al-Sarraf M, Marts K, Herkovic A, et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an itergroup study. J Clin Oncol. 1997;15:277\u201384. https:\/\/doi.org\/10.1200\/JCO.1997.15.1.277.","journal-title":"J Clin Oncol"},{"key":"3382_CR3","doi-asserted-by":"publisher","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ et al. Esophageal and esophagogastric junction cancers. Version 2. 2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2019: 855\u201383. https:\/\/doi.org\/10.6004\/jnccn.2019.0033","DOI":"10.6004\/jnccn.2019.0033"},{"key":"3382_CR4","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.radonc.2021.01.007","volume":"157","author":"TT Huang","year":"2021","unstructured":"Huang TT, Li SH, Chen YH, et al. Definitive chemoradiotherapy for clinical T4b esophageal cancer \u2013 treatment outcomes, failure patterns, and prognostic factors. Radiother Oncol. 2021;157:56\u201362. https:\/\/doi.org\/10.1016\/j.radonc.2021.01.007.","journal-title":"Radiother Oncol"},{"key":"3382_CR5","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1200\/JCO.2005.00.034","volume":"23","author":"M Stahl","year":"2005","unstructured":"Stahl M, Stuschke M, Lehmann N, et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol. 2005;23:2310\u201317. https:\/\/doi.org\/10.1200\/JCO.2005.00.034.","journal-title":"J Clin Oncol"},{"key":"3382_CR6","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1200\/JCO.2005.04.7118","volume":"25","author":"L Bedenne","year":"2007","unstructured":"Bedenne L, Michel P, Bouche O, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25:1160\u201368. https:\/\/doi.org\/10.1200\/JCO.2005.04.7118.","journal-title":"J Clin Oncol"},{"key":"3382_CR7","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1245\/s10434-019-07654-8","volume":"27","author":"T Yokota","year":"2020","unstructured":"Yokota T, Kato K, Hamamoto Y, et al. A 3-year overall survival update from a phase 2 study of chemoselection with DCF and subsequent conversion surgery for local advanced unresectable esophageal cancer. Ann Surg Onclo. 2020;27:460\u201367. https:\/\/doi.org\/10.1245\/s10434-019-07654-8.","journal-title":"Ann Surg Onclo"},{"key":"3382_CR8","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/cas.12274","volume":"104","author":"H Hara","year":"2013","unstructured":"Hara H, Tahara M, Daiko H, et al. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma. Cancer Sci. 2013;104:1455\u201360. https:\/\/doi.org\/10.1111\/cas.12274.","journal-title":"Cancer Sci"},{"key":"3382_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s00280-016-3062-2","volume":"78","author":"H Satake","year":"2016","unstructured":"Satake H, Tahara M, Mochizuki S, et al. A prospective, multicenter phase I\/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemotherapy in patients with unresectable locally advanced esophageal carcinoma. Cancer Chemother Pharmacil. 2016;78:91\u20139. https:\/\/doi.org\/10.1007\/s00280-016-3062-2.","journal-title":"Cancer Chemother Pharmacil"},{"key":"3382_CR10","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1245\/s10434-014-3684-8","volume":"21","author":"M Watanabe","year":"2014","unstructured":"Watanabe M, Baba Y, Yoshida N, et al. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer. Ann Surg Oncol. 2014;21:2838\u201344. https:\/\/doi.org\/10.1245\/s10434-014-3684-8.","journal-title":"Ann Surg Oncol"},{"key":"3382_CR11","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/bjc.2016.350","volume":"115","author":"T Yokota","year":"2016","unstructured":"Yokota T, Kato K, Hamamoto Y, et al. Phase II studi of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer. Br J Cancer. 2016;115:1328\u201334. https:\/\/doi.org\/10.1038\/bjc.2016.350.","journal-title":"Br J Cancer"},{"key":"3382_CR12","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s12957-018-1420-8","volume":"16","author":"Y Akiyama","year":"2018","unstructured":"Akiyama Y, Sasaki A, Endo F, et al. Outcomes of esophagectomy after chemotherapy with biweekly docetaxel cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis. World J Surg Oncol. 2018;16:122\u201329. https:\/\/doi.org\/10.1186\/s12957-018-1420-8.","journal-title":"World J Surg Oncol"},{"key":"3382_CR13","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"354","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;354:1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med"},{"key":"3382_CR14","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomized, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317. https:\/\/doi.org\/10.1016\/S1470-2045(19)30626-6.","journal-title":"Lancet Oncol"},{"key":"3382_CR15","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5.","journal-title":"Lancet"},{"key":"3382_CR16","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomized, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(21)01234-4.","journal-title":"Lancet"},{"key":"3382_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigain","year":"2021","unstructured":"Janjigain YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oeophageal adenocarcinoma (CheckMate 649): a randomized, opne-label, phase 3 trial. Lancet. 2021;398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2.","journal-title":"Lancet"},{"key":"3382_CR18","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449\u201362. https:\/\/doi.org\/10.1056\/NEJMoa2111380.","journal-title":"N Engl J Med"},{"key":"3382_CR19","doi-asserted-by":"publisher","first-page":"2915","DOI":"10.1200\/JCO.1999.17.9.2915","volume":"17","author":"A Ohtsu","year":"1999","unstructured":"Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and\/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915\u201321. https:\/\/doi.org\/10.1200\/JCO.1999.17.9.2915.","journal-title":"J Clin Oncol"},{"key":"3382_CR20","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/S0033-8389(22)02153-4","volume":"27","author":"RA Halvorsen Jr","year":"1989","unstructured":"Halvorsen RA Jr, Thompson WM. CT of esophageal neoplasms. Radiol Clin North Am. 1989;27:667\u201385.","journal-title":"Radiol Clin North Am"},{"key":"3382_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/s1072-7515(00)00757-2","volume":"191","author":"M Yano","year":"2000","unstructured":"Yano M, Shozaki H, Tsujinaka T, et al. Squamous cell carcinoma of the eosphagus infiltrating the respiratory tract is less sensitive to preoperative concurrent radiation and chemotherapy. J Am Cpll Surg. 2000;191:626\u201334. https:\/\/doi.org\/10.1016\/s1072-7515(00)00757-2.","journal-title":"J Am Cpll Surg"},{"issue":"6","key":"3382_CR22","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cas.12148","volume":"104","author":"C Giessen","year":"2013","unstructured":"Giessen C, Laubender RP, von Weikersthal LF, et al. Early tumor shrinkage in metastatic colo-rectal cancer: retrospective analysis from an irrinotecan-based randomized first-line trial. Cancer Sci. 2013;104(6):718\u201324. \/cas.12148.","journal-title":"Cancer Sci"},{"key":"3382_CR23","unstructured":"Shah MA, Sun JM, Shen L et al. First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced esophageal cancer: 5-year outcomes from the phase 3 KEYNOTE-590 study. 2024 ASCO Gastrointestinal Cancers Symposium. January 18, 2024. https:\/\/meetings.asco.org\/2024-asco-gastrointestinal-cancers-symposium\/15565?presentation=229133"},{"key":"3382_CR24","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2002","unstructured":"Kojima T, Shar MA, Muro K, et al. Randomized phase III KEYNOTE-181 study of Pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncl. 2002;38:4138\u201348. https:\/\/doi.org\/10.1200\/JCO.20.01888.","journal-title":"J Clin Oncl"},{"key":"3382_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1038\/s41416-020-0811-0","volume":"122","author":"K Okadome","year":"2020","unstructured":"Okadome K, Baba Y, Nomoto D, et al. Prognostic and clinical impact of PD-L2 and PD-L1 expression in a chohort of 437 oesophageal cancers. Br J Caner. 2020;122:1535\u201343. https:\/\/doi.org\/10.1038\/s41416-020-0811-0.","journal-title":"Br J Caner"},{"key":"3382_CR26","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/cas.15198","volume":"113","author":"K Okadome","year":"2022","unstructured":"Okadome K, Baba Y, Yasuda-Yoshihara N, et al. PD-L1 and PD-l2 expression status in relation to chemotherapy in primary and metastatic esophageal squamous cell carcinoma. Cancer Sci. 2022;113:399\u2013410. https:\/\/doi.org\/10.1111\/cas.15198.","journal-title":"Cancer Sci"},{"key":"3382_CR27","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab for esophageal or GEJ carcinoma. Published March 22, 2021. Accessed January 5, 2022. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-esophageal-or-gej-carcinoma"},{"key":"3382_CR28","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","volume":"28","author":"E Saada-Bouzid","year":"2017","unstructured":"Saada-Bouzid E, Defaucheux C, Karabajakian A, et al. Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma. Ann Oncol. 2017;28:1605\u201311. https:\/\/doi.org\/10.1093\/annonc\/mdx178.","journal-title":"Ann Oncol"},{"key":"3382_CR29","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1007\/s10120-018-00922-8","volume":"22","author":"A Sasaki","year":"2019","unstructured":"Sasaki A, Nakamura Y, Mishima S, et al. Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer. Gastric Cancer. 2019;22:793\u2013802. https:\/\/doi.org\/10.1007\/s10120-018-00922-8.","journal-title":"Gastric Cancer"},{"key":"3382_CR30","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1080\/15384047.2020.1834319","volume":"21","author":"D Sun","year":"2020","unstructured":"Sun D, Liu D, Liu Q, et al. Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinoma. Cancer Biol Ther. 2020;21:1097\u2013104. https:\/\/doi.org\/10.1080\/15384047.2020.1834319.","journal-title":"Cancer Biol Ther"},{"key":"3382_CR31","doi-asserted-by":"publisher","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","volume":"23","author":"S Kato","year":"2017","unstructured":"Kato S, Goodman A, Walavalkar V, et al. Hyperprogression after immunotherapy: analysis of genomic alterations associated with accelerated growth rate. Clin Cancer Res. 2017;23:4242\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3133.","journal-title":"Clin Cancer Res"},{"key":"3382_CR32","doi-asserted-by":"publisher","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","volume":"15","author":"JD Wolchok","year":"2009","unstructured":"Wolchok JD, Hoos A, O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1624.","journal-title":"Clin Cancer Res"},{"key":"3382_CR33","doi-asserted-by":"publisher","first-page":"2174","DOI":"10.1158\/1078-0432.CCR-18-3206","volume":"25","author":"JC Pignon","year":"2019","unstructured":"Pignon JC, Jegede O, Shukla SA, et al. irRECIST fir the evaluation of candidate biomarkers of response to Nivolumab in metastatic clear cell renal carcinoma: analysis of a phase II prospective clinical trial. Cin Cancer Res. 2019;25:2174\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-3206.","journal-title":"Cin Cancer Res"},{"key":"3382_CR34","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","volume":"18","author":"L Seymour","year":"2017","unstructured":"Seymour L, Bogaerts J, Perrone A, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18:e143\u201352. https:\/\/doi.org\/10.1016\/S1470-2045(17)30074-8.","journal-title":"Lancet Oncol"},{"key":"3382_CR35","unstructured":"Ma Y, Wang Q, Dong Q et al. How to differentiate pseudoprogression from true progression in cancer patients with immunotherapy. Am J Cancer Res. 2019;1;9(8): 1546-53. PMCID: PMC6726978."}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03382-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-024-03382-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-024-03382-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T15:02:37Z","timestamp":1725289357000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-024-03382-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3382"],"URL":"https:\/\/doi.org\/10.1186\/s12876-024-03382-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3050447\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"11 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The current study was approved by the Ethics Committee of Teikyo University School of Medicine and performed in accordance with the guidelines approved by The Japan Esophageal Society. All patients provided their written informed consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}